Callan Family Office LLC Takes $381,000 Position in The Cooper Companies, Inc. (NASDAQ:COO)

Callan Family Office LLC purchased a new position in shares of The Cooper Companies, Inc. (NASDAQ:COO - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 4,144 shares of the medical device company's stock, valued at approximately $381,000.

A number of other hedge funds have also bought and sold shares of the company. Ashton Thomas Securities LLC acquired a new position in shares of Cooper Companies in the 3rd quarter valued at about $25,000. Byrne Asset Management LLC bought a new position in shares of Cooper Companies during the fourth quarter valued at approximately $33,000. Covestor Ltd raised its position in shares of Cooper Companies by 144.9% during the 3rd quarter. Covestor Ltd now owns 338 shares of the medical device company's stock worth $37,000 after purchasing an additional 200 shares during the period. Brown Brothers Harriman & Co. lifted its holdings in shares of Cooper Companies by 191.0% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 419 shares of the medical device company's stock worth $46,000 after purchasing an additional 275 shares during the last quarter. Finally, West Financial Advisors LLC acquired a new position in Cooper Companies during the 4th quarter valued at approximately $49,000. 24.39% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Morgan Stanley reduced their price target on shares of Cooper Companies from $104.00 to $102.00 and set an "equal weight" rating for the company in a report on Friday, December 6th. Citigroup reduced their target price on shares of Cooper Companies from $115.00 to $110.00 and set a "buy" rating for the company in a research note on Friday, March 7th. Stifel Nicolaus dropped their price target on shares of Cooper Companies from $115.00 to $105.00 and set a "buy" rating on the stock in a research note on Friday, March 7th. Needham & Company LLC reaffirmed a "hold" rating on shares of Cooper Companies in a report on Friday, March 7th. Finally, Robert W. Baird decreased their price objective on Cooper Companies from $117.00 to $107.00 and set an "outperform" rating for the company in a report on Friday, March 7th. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $111.89.

Remove Ads

Cooper Companies Price Performance

COO traded up $3.49 during trading on Friday, reaching $81.22. The stock had a trading volume of 2,436,699 shares, compared to its average volume of 1,255,824. The Cooper Companies, Inc. has a 1-year low of $76.46 and a 1-year high of $112.38. The firm has a market capitalization of $16.21 billion, a price-to-earnings ratio of 41.65, a price-to-earnings-growth ratio of 2.25 and a beta of 1.02. The stock has a 50 day moving average of $91.67 and a two-hundred day moving average of $99.11. The company has a quick ratio of 1.12, a current ratio of 1.91 and a debt-to-equity ratio of 0.32.

Cooper Companies (NASDAQ:COO - Get Free Report) last announced its quarterly earnings data on Thursday, March 6th. The medical device company reported $0.92 earnings per share for the quarter, meeting the consensus estimate of $0.92. The business had revenue of $964.70 million during the quarter, compared to analyst estimates of $981.25 million. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. As a group, equities analysts anticipate that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.